Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2020 Jul 14:2020.07.12.20151068. [Version 1] doi: 10.1101/2020.07.12.20151068

Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19

Stuart P Weisberg, Thomas Connors, Yun Zhu, Matthew Baldwin, Wen-Hsuan Lin, Sandeep Wontakal, Peter A Szabo, Steven B Wells, Pranay Dogra, Joshua I Gray, Emma Idzikowski, Francesca Bovier, Julia Davis-Porada, Rei Matsumoto, Maya Meimei Li Poon, Michael P Chait, Cyrille Mathieu, Branka Horvat, Didier Decimo, Zachary C Bitan, Francesca La Carpia, Stephen A Ferrara, Emily Mace, Joshua Milner, Anne Moscona, Eldad A Hod, Matteo Porotto, Donna L Farber
PMCID: PMC7373150  PMID: 32699861

Abstract

Clinical manifestations of COVID-19 caused by the novel coronavirus SARS-CoV-2 are associated with age. While children are largely spared from severe respiratory disease, they can present with a SARS-CoV-2-associated multisystem inflammatory syndrome (MIS-C) similar to Kawasaki's disease. Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease. There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while both COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs. Moreover, MIS-C patients had reduced neutralizing activity compared to COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES